Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIDAs: metabolic impact of switching suppressed HIV-1 patients from Atripla to darunavir/ritonavir monotherapy
2010-022120-72Phase 4Completed
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of darunavir, ritonavir, efavirenz, emtricitabine and tenofovir disoproxil fumarate in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Guy's and St Thomas' NHS Foundation Trust. Primary endpoint: Change in 25-hydroxyvitamin D. Started Nov 2010; status: completed.
02
Drugs
darunavirritonavirefavirenzemtricitabinetenofovir disoproxil fumarate
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2010-022120-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022120-72.